Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma
Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma
复制标题
DOI：
10.4254/wjh.v6.i11.818
复制
发表时间：
2014-11-27
影响因子：
2.4
通讯作者：
Omar, Heba
中科院分区：
文献类型：
--
作者：
El-Garem, Hassan;Ammer, Ayman;Omar, Heba
目的：探讨血清miR-122和miR-221作为丙型肝炎病毒相关性肝细胞癌无创诊断标志物的潜在价值。方法：对90例成年丙型肝炎相关性慢性肝病和慢性丙型肝炎相关性肝癌患者进行前瞻性研究。除10例健康对照组外，将患者分为干扰素初治的慢性丙型肝炎(CH)组(n=30)、丙型肝炎后代偿期肝硬变(LC)组(n=30)和治疗初治的肝癌组(n=30)。结果：与正常对照组相比，不同患者组血清miRNA表达水平均有显著差异，肝细胞癌和肝细胞癌miR-122表达均显著增加，而肝细胞癌miR-122表达均显著降低。而在肝细胞癌和肝细胞癌中，miR-221表达均显著升高(P=0.01)，肝细胞癌中miR-221表达显著降低(P=0.01)。比较肝细胞癌组与非肝细胞癌组miRNAs的倍数变化，发现肝细胞癌组miR-122的倍数无明显升高(P=0.21)，miR-221的倍数显著降低(P=0.03)。以1.82作为临界值，ROC曲线分析miR-221鉴别肝癌与非肝癌的敏感度为87%，特异度为40%。结论：血清miR-221有望成为一种新的无创肝细胞癌标志物。(C)2014百仕登出版集团有限公司，版权所有。
AIM: To explore the potential usefulness of serum miR-122 and miR-221 as non-invasive diagnostic markers of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).METHODS: This prospective study was conducted on 90 adult patients of both sex with HCV-related chronic liver disease and chronic hepatitis C related HCC. In addition to the 10 healthy control individuals, patients were stratified into; interferon-naive chronic hepatitis C (CH) (n = 30), post-hepatitis C compensated cirrhosis (LC) (n = 30) and treatment-naive HCC (n = 30). All patients and controls underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miRNA expression by RT-PCR.RESULTS: There was a significant fold change in serum miRNA expression in the different patient groups when compared to normal controls; miR-122 showed significant fold increasing in both CH and HCC and significant fold decrease in LC. On the other hand, miR-221 showed significant fold elevation in both CH and LC groups and significant fold decrease in HCC group (P = 0.01). Comparing fold changes in miRNAs in HCC group vs non HCC group (CH and Cirrhosis), there was non-significant fold elevation in miR-122 (P = 0.21) and significant fold decreasing in miR-221 in HCC vs non-HCC (P = 0.03). ROC curve analysis for miR-221 yielded 87% sensitivity and 40% specificity for the differentiation of HCC patients from non-HCC at a cutoff 1.82.CONCLUSION: Serum miR-221 has a strong potential to serve as one of the novel non-invasive biomarkers of HCC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.